Skip to content
value.today
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc.

🇺🇸 La Jolla, California, USABiotechnologyFounded 2017
Total raised
$192 M
3 rounds on record
Latest round
$125 M
Apr 2021
First round on record
Jun 2020
Today
Went public
See the company page

Janux Therapeutics, Inc. is listed today as Janux Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Janux Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2021$125 MNo. 3$50 to $250 million

Janux Therapeutics, Inc.: Raise no. 3, Apr 2021

Investors in this round

22 investors had bought by the notice of Apr 30, 2021: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Janux Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$125 M of $125 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Campbell, Ph.D. · Executive Officer, Director
  • Tighe Reardon · Executive Officer
  • Jake Simson, Ph.D. · Director
  • Jay Lichter, Ph.D. · Director
  • Peter Thompson, M.D. · Director
  • Sheila Gujrathi · Director
  • Stefan Heller · Director
  • Vickie L. Capps · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Campbell, Ph.D., President and CEO. Source: SEC Form D, newest notice filed Apr 30, 2021. Read the notice at the SEC.

equitySEC
Mar 2021$56 MNo. 2$50 to $250 million

Janux Therapeutics, Inc.: Raise no. 2, Mar 2021

Investors in this round

7 investors had bought by the notice of Mar 12, 2021: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Janux Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$56 M of $56 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Campbell, Ph.D. · Executive Officer, Director
  • Tighe Reardon · Executive Officer
  • Jake Simson, Ph.D. · Director
  • Jay Lichter, Ph.D. · Director
  • Peter Thompson, M.D. · Director
  • Stefan Heller · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Campbell, Ph.D., President and CEO. Source: SEC Form D, newest notice filed Mar 12, 2021. Read the notice at the SEC.

equitySEC
Jun 2020$11 MNo. 1$10 to $50 million

Janux Therapeutics, Inc.: Raise no. 1, Jun 2020

Investors in this round

3 investors had bought by the notice of Jul 14, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Janux Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $16 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Campbell, Ph.D. · Executive Officer, Director
  • Tighe Reardon · Executive Officer
  • Jay Lichter, Ph.D. · Director
  • Stefan Heller · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount and Total Amount Sold include amounts paid pursuant to conversion of indebtedness.”

Signed by David Campbell, President and CEO. Source: SEC Form D, newest notice filed Jul 14, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Janux Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2021).

    SEC Form D · Apr 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2021

That is all the official record says: Janux Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Janux Therapeutics, Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Janux Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Avalon BioVentures SPV I, L.P.Venture capitalnot statednot statedHeld Series Seed, A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Avalon Ventures XI, L.P.Venture capitalnot statednot statedHeld Series Seed, A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Bregua CorpCompanynot statednot statedHeld Series Seed, A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, director (Form 3, 2021)SEC Form 3
OrbiMed Capital GP VIII LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, director (Form 3, 2021)SEC Form 3
OrbiMed Genesis GP LLCOthernot statednot statedHeld Series A and B preferred stock, director (Form 3, 2021)SEC Form 3
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 22 investors.

Largest shareholders today

Institutions holding Janux Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Janux Therapeutics, Inc.
NameRoleNamed in
David Campbell, Ph.D.Executive officerApr 2021
Tighe ReardonExecutive officerApr 2021
David Campbell, Ph.D.DirectorApr 2021
Jake Simson, Ph.D.DirectorApr 2021
Jay Lichter, Ph.D.DirectorApr 2021
Peter Thompson, M.D.DirectorApr 2021
Sheila GujrathiDirectorApr 2021
Stefan HellerDirectorApr 2021
Vickie L. CappsDirectorApr 2021

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.